Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diazoxide Pilot & Feasibility Study in NAFLD
NCT05729282Phase 1Completed
- Sponsor
- Columbia University
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diazoxide in non-alcoholic fatty liver disease (NAFLD), hyperinsulinemia and insulin resistance (IR) (3 arms), sponsored by Columbia University. Primary endpoints: Fasting Plasma Glucose (Absolute Values), Fasting Plasma Glucose (Fold Change) and 2 more. Started Aug 2023; status: completed.
02
Drugs
diazoxide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)hyperinsulinemiainsulin resistance (IR)
Beyond the preview
Go deeper on NCT05729282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729282.